“…The observation that DCC expression was lost/reduced in colorectal cancer suggested that DCC presence is a negative constraint for tumor development. Along this line, LOH of chromosome 18q and/or decreased DCC expression have also been detected in various other cancers, including gastric (Uchino et al, 1992) (Fang et al, 1998) (Yoshida et al, 1998), prostate (Brewster et al, 1994) (Latil et al, 1994) (Latil et al, 2003), endometrial (Imamura et al, 1992) (Gima et al, 1994) (Saegusa et al, 1999), ovarian (Enomoto et al, 1995) (Saegusa et al, 2000), esophageal (Huang et al, 1992) (Dolan et al, 1998), breast (Devilee et al, 1991) (Thompson et al, 1993), testicular (Murty et al, 1994) (Strohmeyer et al, 1997), glial (Scheck andCoons, 1993) (Reyes-Mugica et al, 1997), neuroblastoma (Kong et al, 1997) (Reyes-Mugica et al, 1998, and hematologic (Porfiri et al, 1993) (Miyake et al, 1993) (Miyake et al, 1994) malignancies. In most of studies, chromosome 18q LOH and loss of DCC expression have been associated with poor prognosis in colorectal cancer patients (Jen et al, 1994) (Lanza et al, 1998) (Sun et al, 1999) (Saito et al, 1999) (Saw et al, 2002) and with decreased responsiveness to chemotherapeutic agent like 5-fluorouracil-based adjuvant (Barratt et al, 2002).…”